Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q

Epidermal growth factor receptor (EGFR) L718Q is a rare resistant mutation which independently leads to third-generation tyrosine kinase inhibitor (TKI) resistance. Although a few studies have examined its resistance mechanisms, no effective treatment strategy has yet been proposed for patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yang, Jia, Ziqi, Wang, Yadong, Wang, Yanyu, Liu, Peng, Zhang, Shuyang, Bing, Zhongxing, Cao, Lei, Cao, Zhili, Rossi, Elisabetta, Zamarchi, Rita, Denis, Marc G., Camps, Carlos, Fernandez-Diaz, Amaya B., Liang, Naixin, Li, Shanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
iMDT Corner
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330377/
https://www.ncbi.nlm.nih.gov/pubmed/32642185
http://dx.doi.org/10.21037/jtd.2020.03.29

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330377/
https://www.ncbi.nlm.nih.gov/pubmed/32642185
http://dx.doi.org/10.21037/jtd.2020.03.29

Ejemplares similares